No analysts currently cover PDS Biotechnology with a public price target. We add the price target automatically as soon as at least one analyst publishes a rating. Until then, use the technical analysis and the key figures below.
2 analysts cover PDS Biotechnology. There is broad agreement on a positive view — 100% recommend buying.
PDS Biotechnology is classified as a momentum stock with a momentum score in the top 20% of all stocks. The price has risen 0.0% over the long term.
The P/B ratio is 3.5.
The Piotroski score is 2 out of 9 — weak financial health, be careful. Altman Z2 is -111.49 (weak balance sheet — elevated risk). The debt-to-equity ratio (D/E) is 138.7% — moderate debt.
Short interest is 3.93%.
In 2026, insiders at PDS Biotechnology have made 3 transactions, all of which were purchases. On a net basis, insiders put $72,501 into the stock. Active insiders include Glover Stephen C., Freitag Gregory Gene, HILL MATTHEW C.
There has been no insider trading in the last 3 months.
Insiders have exclusively bought shares.
Across the last 3 transactions: 3 purchases and 0 sales. A net $72,501 into the stock.
Latest purchase: Glover Stephen C. bought 15,061 shares at $1.66 each on 2025-02-28. The stock has since fallen 33.1%.
Who is buying: Glover Stephen C., Freitag Gregory Gene, HILL MATTHEW C.
The table shows the last 3 reported insider transactions in PDS Biotechnology. Green rows are purchases, red rows are sales. The data is based on official filings.
| Transaction date | Name | Type | Number of shares | Price per share ($) | Total amount ($) |
|---|---|---|---|---|---|
| 2025-02-28 | Glover Stephen C. | Buy | 15,061 | 2 | 25,001 |
| 2025-02-28 | Freitag Gregory Gene | Buy | 15,060 | 2 | 25,000 |
| 2021-12-13 | HILL MATTHEW C | Buy | 2,500 | 9 | 22,500 |
The following insiders have bought shares in PDS Biotechnology: Glover Stephen C., Freitag Gregory Gene, HILL MATTHEW C. In total, $72,501 was bought across 3 transactions. Insider trades are legal transactions in which executives and board members buy or sell shares of their own company. These transactions are reported to the SEC and are publicly available.
Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated October 26, 2026.
PDS Biotechnology Corporation is in a short-term uptrend. The price of $1.11 is 1.9% above the 20-day average ($1.09). Medium term, the picture is positive: the price is 62.3% above the 50-day average ($0.68). Long term, the stock is 35.4% above the 200-day average ($0.82), which confirms a long-term uptrend.
Death Cross: The 50-day average (0.68) is below the 200-day average (0.82), which is a classic bearish signal for PDS Biotechnology Corporation.
PDS Biotechnology Corporation has an RSI of 53.4, right in the middle of the neutral zone. There is no clear buying or selling pressure.
Daily MACD: MACD is positive (0.120), which means the short-term trend is bullish (the 12-day EMA is above the 26-day EMA). MACD is below the signal line (0.155) by 0.035, which suggests the positive momentum is fading – the trend could be turning.
Weekly MACD: MACD5 is positive (0.033), which indicates a broader bullish long-term trend. MACD5 is above the signal line (-0.063) by 0.096, which confirms rising long-term momentum.
Overall MACD assessment: Both the daily and weekly trend are bullish (MACD positive). However, momentum shows signs of weakening on a daily basis. Watch whether the trend holds.
PDS Biotechnology Corporation has an annual standard deviation of 174.4%, which classifies the stock as Extremely speculative. Only risk-tolerant investors should consider this stock, because the price swings can be very large.
Trend: Neutral/mixed.
MACD trend (zero line): Daily bullish (0.120). Weekly bullish (0.033).
MACD momentum (signal): Daily falling. Weekly rising.
RSI: 53.4 – neutral.
Technical signal: Buy
The broader trend is positive and MACD supports the picture. Consider buying with a stop-loss below the nearest support level.
Compare PDS Biotechnology with other stocks in the healthcare sector. Click a stock to see its technical analysis, insider trading and key figures.
See all 115 stocks in the Healthcare sector